Fetal Goitre in Maternal Graves' Disease A.M
Total Page:16
File Type:pdf, Size:1020Kb
1300 EDITORIAL doi: 10.4183/aeb.2018.85 FETAL GOITRE IN MATERNAL GRAVES’ DISEASE A.M. Panaitescu1,*, K. Nicolaides2 1Filantropia Hospital, Bucharest, Romania, 2Fetal Medicine Research Institute, King’s College Hospital, London, UK Abstract to the fetus and increasing requirements for maternal Fetal goitre is found in about 1 in 5,000 births, hormone production; the gland itself may increase in usually in association with maternal Graves’ disease, due to size up to 40% in some women thus decreasing serum transplacental passage of high levels of thyroid stimulating thyroglobulin. Also, iodine clearance is increased antibodies or of anti-thyroid drugs. A goitre can cause during pregnancy making hormone production in complications attributable to its size and to the associated iodine deficient areas potentially insufficient (1). thyroid dysfunction. Fetal ultrasound examination allows easy recognition of the goitre but is not reliable in Changes in the thyroid hormones during distinguishing between fetal hypo- and hyperthyroidism. pregnancy relate to the necessity of delivering thyroxine Assessment of the maternal condition and, in some cases, to the fetus, especially to the fetal brain. Maternal T4 is cordocentesis provide adequate diagnosis of the fetal thyroid effectively metabolised into inactive reverse T3 by the function. First-line treatment consists of adjusting the dose placenta, however a small but physiologically relevant of maternal anti-thyroid drugs. Delivery is aimed at term. In amount of T4 is still transferred to the fetus and this is cases with large goitres, caesarean-section is indicated. essential for normal fetal development (2). Normal fetal brain development depends on maternal derived T4 at Key words: Graves’ disease, fetal goitre, fetal least until 16 weeks’ gestation when the fetal thyroid thyroid, pregnancy. starts to produce the thyroid hormones.(3) In the fetal brain deiodinase type 2 is found in high levels and is responsible for converting T4 to active T3, thus making INTRODUCTION it readily available (3). In healthy women thyroid physiological changes happen seamlessly, however in The thyroid gland undergoes extensive changes cases with uncorrected thyroid dysfunction there may during pregnancy, delivery and lactation. These be deleterious effects on the fetus during pregnancy changes are supported by the interaction between the such as development of fetal hypo- or hyperthyroidism fetal-placental unit and the maternal endocrine system or fetal goitre and long term neurodevelopmental (Fig. 1) and are reflected in the thyroid function tests, sequalae (4). which differ from outside pregnancy as early as first Along with gestational and preexisting diabetes, trimester. During pregnancy, there is an increase in thyroid disorders are the most common endocrine thyroid binding globulin which leads to increased disorders in pregnant women (5). Hypothyroidism, levels of serum thyroid hormones (T4 - thyroxine and either clinical or subclinical, is encountered in about T3 - tri-iodothyronine); the placenta produces hCG 2-3% of pregnant women (6). Thyrotoxicosis is also (human chorionic gonadotrophin), a glycoprotein common and is usually due to Graves’ disease, but hormone with molecular similarity of its α-subunit during the first part of pregnancy may also be the with TSH (thyroid stimulating hormone) which acts consequence of elevated hCG levels (7) (gestational as an agonist of TSH raising transiently free T4 levels transient thyrotoxicosis) and is often associated with and decreasing serum TSH levels; plasma volume hyperemesis gravidarum. expands thus increasing total T4 and T3 pool size; This review will only discuss maternal Graves’ in the placenta, type 3 iodothyronine deiodinase is disease and its fetal consequences and will focus on the highly expressed converting T4 into inactive reverse management of prenatally detected fetal goitre in the T3 and thus controlling the availability of T3 and T4 case of maternal Graves’ disease. *Correspondence to: Anca Maria Panaitescu MD, Filantropia Hospital, 11 Ion Mihalache Blvd., Bucharest, 011161, Romania, E-mail: [email protected] Acta Endocrinologica (Buc), vol. XIV, no. 1, p. 85-89, 2018 85 A.M. Panaitescu and K. Nicolaides Graves’ disease during pregnancy treatment, radioiodine therapy or surgical removal Graves’ disease is an autoimmune disorder of the gland in those affected by Graves’ disease. characterised by the presence of immunoglobulins Therefore, indications for testing for thyroid stimulating that bind the TSH receptors in the thyroid gland and immunoglobulins in pregnant women with known stimulate the production of thyroid hormones leading to Graves’ disease include (a) mothers with untreated hyperthyroidism (the occurrence of inhibiting antibodies or drug-treated hyperthyroidism in pregnancy, (b) a being exceptional). Affected individuals are treated by previous history of Graves’ disease with past treatment radioiodine therapy or surgical removal of the gland with radioiodine or total thyroidectomy, (c) a previous followed by the administration of the synthetic thyroid history of delivering an infant with hyperthyroidism, or hormone levothyroxine. Some patients are treated by (d) a known history of thyroidectomy for the treatment anti-thyroid drugs, such as propylthiouracil, carbimazole of hyperthyroidism in pregnancy. A level of antibodies and methimazole; these drugs inhibit the enzyme of 3 times the upper limit of normal is an indication thyroperoxidase which facilitates the addition of iodine for establishing close follow-up of the fetus (10). Anti- to tyrosine in the production of thyroglobulin (Fig. 1), an thyroid drugs used during pregnancy can also cross the essential step in the formation of thyroid hormones. placenta and may be teratogenic and act on the fetal Graves’ disease is found in 1 in 500 pregnant thyroid gland, leading to hypothyroidism and fetal women (8). During pregnancy, thyroid stimulating goitre. If possible, it is recommended that anti-thyroid immunoglobulins can cross the placenta by using medication is avoided in the first trimester of pregnancy the physiological maternal-fetal antibody transfer and this can be achieved in some stable cases of pathways (9) and can act on the fetal thyroid gland Graves’ disease as the general autoimmunity decreases resulting in the development of fetal hyperthyroidism during pregnancy (11). However, when treatment and sometimes to fetal goitre. Thyroid stimulating is necessary, propylthiouracil is generally favoured immunoglobulins may persist for years after medical due to its safer fetal profile compared to carbimazole and methimazole which have been associated with development of aplasia cutis, choanal and oesophageal atresia, abdominal wall defects and ventricular septal defects. After the first trimester, consideration can be given to switching to carbimazole or methimazole to decrease the risk of liver failure in the mother (10). Fetal goitre The exact incidence of fetal goitre is not P<0.05 is considered as significant known but it may be up to 1 in 5,000 births, usually, but not exclusively, in association with maternal Graves’ disease (12). Thus, the incidence of Graves’ disease during pregnancy is about 1 in 500 (8) and incidence of fetal goitre in mothers with treated or untreated Graves’ disease is about 10% (13-17). Thyroid stimulating immunoglobulins in maternal Graves’ disease can cross the placenta and act Figure 1. Production of thyroid hormones and its control. The hypothalamus produces thyroid releasing hormone (TRH) which on the fetal thyroid gland resulting in the development stimulates the pituitary gland to release thyroid stimulating of fetal hyperthyroidism and in some cases of fetal hormone (TSH) which acts on TSH receptors on the thyroid gland goitre. However, most cases of fetal thyroid goitre are and stimulates the production of thyroid hormones. They in turn the consequence of fetal hypothyroidism due to trans- control their production through negative feedback on both the hypothalamus and pituitary gland. During pregnancy, the placenta placentally derived anti-thyroid drugs used for the produces human chorionic gonadotrophin (hCG) which stimulates treatment of maternal hyperthyroidism. (13-15). the TSH receptor. Placenta controls the availability of maternal Less common causes of fetal goitre are thyroid hormones to the fetus through the enzyme iodothyronine inadequate or excessive iodine availability (18) or deiodinase type 3 (D3) which inactivates T4 and T3. A small, but physiologically relevant amount of T4 is transferred from the congenital thyroid dyshormonogenesis due to defects mother to the fetus. This is essential for normal early neurological in genes involved in the pathway of thyroid hormone fetal development. Within the fetal brain, deiodinase type 2 is production (19). specifically expressed and converts T4 into active T3. 86 Fetal goitre in maternal Graves Ultrasound diagnosis fetal hypothyroidism or hyperthyroidism. In uncertain Fetal goitre can be diagnosed prenatally by cases, cordocentesis and measurement of fetal blood ultrasound with the demonstration of an anterior thyroid hormones and TSH can help distinguish cervical echogenic mass of variable size (Fig. 2). Large between hypothyroidism, with low thyroid hormones fetal goitres may lead to obstruction of fetal swallowing and high TSH, due to anti-thyroid drugs or congenital with consequent polyhydramnios; the neck may be dyshormonogenesis, and hyperthyroidism, with